Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo.
Therapeutic angiogenesis using vascular endothelial growth factor (VEGF) is considered a promising new therapy for patients with arterial obstructive disease. Clinical improvements observed consist of improved muscle function and regression of rest pain or angina. However, direct evidence for improved vascularization, as evaluated by angiography, is weak. In this study, we report an angiogenesis-independent effect of VEGF on ischemic skeletal muscle, ie, upregulation of myoglobin after VEGF treatment. Mice received intramuscular injection with adenoviral VEGF-A or either adenoviral LacZ or PBS as control, followed by surgical induction of acute hindlimb ischemia at day 3. At day 6, capillary density was increased in calf muscle of Ad.VEGF-treated versus control mice (P<0.01). However, angiographic score of collateral arteries was unchanged between Ad.VEGF-treated and control mice. More interestingly, an increase in myoglobin was observed in Ad.VEGF-treated mice. Active myoglobin was 1.5-fold increased in calf muscle of Ad.VEGF-treated mice (P< or =0.01). In addition, the number of myoglobin-stained myofibers was 2.6-fold increased in Ad.VEGF-treated mice (P=0.001). Furthermore, in ischemic muscle of 15 limb amputation patients, VEGF and myoglobin were coexpressed. Finally, in cultured C2C12 myotubes treated with rhVEGF, myoglobin mRNA was 2.8-fold raised as compared with PBS-treated cells (P=0.02). This effect could be blocked with the VEGF receptor tyrosine kinase inhibitor SU5416. In conclusion, we show that VEGF upregulates myoglobin in ischemic muscle both in vitro and in vivo. Increased myoglobin expression in VEGF-treated muscle implies an improved muscle oxygenation, which may, at least partly, explain observed clinical improvements in VEGF-treated patients, in the absence of improved vascularization.
van Weel
Vincent
V
Gaubius Laboratory TNO-PG, PO Box 2215 2301CE, Leiden, the Netherlands. PHA.Quax@pg.tno.nl
Deckers
Martine M L
MM
Grimbergen
Jos M
JM
van Leuven
Kees J M
KJ
Lardenoye
JanWillem H P
JH
Schlingemann
Reinier O
RO
van Nieuw Amerongen
Geerten P
GP
van Bockel
J Hajo
JH
van Hinsbergh
Victor W M
VW
Quax
Paul H A
PH
D000256:Adenoviridae / Q000235:genetics; D000368:Aged; D000671:Amputation, Surgical; D000818:Animals; D002196:Capillaries / Q000254:growth & development; D005260:Female; D015870:Gene Expression; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007511:Ischemia / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000628:therapy; D008297:Male; D051379:Mice; D008875:Middle Aged; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000378:metabolism; D018482:Muscle, Skeletal / Q000033:anatomy & histology / Q000098:blood supply* / Q000378:metabolism; D009211:Myoglobin / Q000096:biosynthesis* / Q000235:genetics; D018919:Neovascularization, Physiologic; D012333:RNA, Messenger / Q000096:biosynthesis; D011859:Radiography; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics* / Q000378:metabolism / Q000494:pharmacology
D009211:Myoglobin; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A